Enliven Therapeutics Inc
(ELVN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,724 | -37,662 | -28,112 | -17,558 | -8,669 |
| Depreciation Amortization | 67 | 215 | 151 | 91 | 39 |
| Accounts payable and accrued liabilities | 492 | 411 | 393 | -965 | -1,557 |
| Other Working Capital | -8,449 | 438 | -168 | -1,373 | -2,385 |
| Other Operating Activity | 1,770 | 4,521 | 3,804 | 2,320 | 2,211 |
| Operating Cash Flow | $-20,844 | $-32,077 | $-23,932 | $-17,485 | $-10,361 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -31 | -612 | -511 | -497 | -194 |
| Investing Cash Flow | $-31 | $-612 | $-511 | $-497 | $-194 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 140 | 591 | 578 | 578 | 573 |
| Other Financing Activity | 237,301 | -2,390 | 0 | -164 | -164 |
| Financing Cash Flow | $237,441 | $-1,799 | $578 | $414 | $409 |
| Beginning Cash Position | 75,590 | 110,078 | 110,078 | 110,078 | 110,078 |
| End Cash Position | 292,156 | 75,590 | 86,213 | 92,510 | 99,932 |
| Net Cash Flow | $216,566 | $-34,488 | $-23,865 | $-17,568 | $-10,146 |
| Free Cash Flow | |||||
| Operating Cash Flow | -20,844 | -32,077 | -23,932 | -17,485 | -10,361 |
| Capital Expenditure | -31 | -612 | -511 | -497 | -194 |
| Free Cash Flow | -20,875 | -32,689 | -24,443 | -17,982 | -10,555 |